XML 38 R25.htm IDEA: XBRL DOCUMENT v3.24.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
In the third quarter of 2023, we completed the implementation of a new operating model intended to simplify and streamline our operations and better align our manufacturing and supply chain to our commercial activities. Under this new operating model, our business is currently comprised of four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care (which we are planning to divest through the pending sale and accordingly, the results are reported in discontinued operations as discussed in Note 1).
The Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Other sales not allocated to a segment primarily include sales of products and services provided directly through certain of our manufacturing facilities and royalty income under a business development arrangement that ended in early 2023 when we acquired the related product rights.
Disaggregation of Net Sales
The following tables present our U.S. and International disaggregated net sales. Intersegment sales, which are eliminated in consolidation, are not presented in the table below.
Three Months Ended September 30,
20242023
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Infusion Therapies and Technologies
$613 $457 $1,070 $570 $433 $1,003 
Advanced Surgery
149 123 272 139 116 255 
Medical Products and Therapies762 580 1,342 709 549 1,258 
Care and Connectivity Solutions
335 121 456 317 126 443 
Front Line Care
222 74 296 234 67 301 
Healthcare Systems and Technologies
557 195 752 551 193 744 
Injectables and Anesthesia
178 143 321 195 156 351 
Drug Compounding— 267 267 — 229 229 
Pharmaceuticals178 410 588 195 385 580 
Other3 14 17 12 5 17 
Total Baxter$1,500 $1,199 $2,699 $1,467 $1,132 $2,599 
Nine Months Ended September 30,
20242023
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Infusion Therapies and Technologies
$1,718 $1,363 $3,081 $1,654 $1,264 $2,918 
Advanced Surgery
446 366 812 433 340 773 
Medical Products and Therapies2,164 1,729 3,893 2,087 1,604 3,691 
Care and Connectivity Solutions
945 365 1,310 926 381 1,307 
Front Line Care
635 222 857 681 230 911 
Healthcare Systems and Technologies
1,580 587 2,167 1,607 611 2,218 
Injectables and Anesthesia
566 424 990 550 437 987 
Drug Compounding— 778 778 — 665 665 
Pharmaceuticals566 1,202 1,768 550 1,102 1,652 
Other30 25 55 56 17 73 
Total Baxter$4,340 $3,543 $7,883 $4,300 $3,334 $7,634 

Geographic Sales Information
Our net sales are attributed to the following geographic regions based on the location of the customer.
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
United States$1,500 $1,467 $4,340 $4,300 
Emerging markets1
347 353 1,001 985 
Rest of world2
852 779 2,542 2,349 
Total Baxter$2,699 $2,599 $7,883 $7,634 
1 Emerging markets includes sales from our operations in Eastern Europe, the Middle East, Africa, Latin America, and Asia (except for Japan).
2 Rest of world includes sales from our operations in Western Europe, Canada, Japan, Australia, and New Zealand.
Segment Operating Income
We use segment operating income to evaluate the performance of our segments and to make resource allocation decisions. Segment operating income represents income before income taxes, interest and other non-operating income or expense, unallocated corporate costs, intangible asset amortization, and other special items. Special items, which are presented below in our reconciliations of segment operating income to income from continuing operations before income taxes, are excluded from segment operating income because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period.
Most global functional support costs, overhead costs and other shared costs that benefit our segments are allocated to those segments. Corporate costs that are not allocated to our segments, as well as any differences between actual corporate costs and the amounts allocated to our segments, are presented as unallocated corporate costs. With the results of our Kidney Care segment reported in discontinued operations, corporate costs that had previously been allocated to the Kidney Care segment which will not convey with the Kidney Care segment in the pending sale, are
now presented as unallocated corporate costs. The following table presents our segment operating income and reconciliations of segment operating income to income from continuing operations before income taxes.
Three Months Ended September 30,Nine Months Ended September 30,
(in millions)2024202320242023
Medical Products and Therapies$268 $245 $733 $706 
Healthcare Systems and Technologies136 115 323 327 
Pharmaceuticals58 108 211 284 
Other2 6 15 19 
Total464 474 1,282 1,336 
Unallocated corporate costs(73)(73)(227)(285)
Intangible asset amortization expense(159)(147)(471)(434)
Legal matters(17)(13)(17)(13)
Business optimization items(18)(48)(49)(167)
Acquisition and integration items(5)(2)(16)(2)
European Medical Devices Regulation(9)(12)(25)(32)
Hurricane Helene costs(25)— (25)— 
Product-related items(3)— (3)— 
Total operating income 155 179 449 403 
Interest expense, net87 127 251 367 
Other (income) expense, net(1)(12)(34)15 
Income from continuing operations before income taxes$69 $64 $232 $21 
Our chief operating decision maker does not receive any asset information by reportable segment and, accordingly, we do not report asset information by reportable segment.